AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26822791
Drug: Dronabinol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (5 mg, twice daily)
Trial: 24062400
Drug: Minimal Residual
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Residual Disease (MRD) evaluation in bone marrow samples after consolidation therapy
Trial: 22288153
Drug: Ladasten (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ladasten (15 mg)
Trial: 19637398
Drug: Buspirone (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (15-30 mg/day)
Trial: 22129365
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg once daily; open-label treatment for ≥24 months; dose reduction to 4 mg and re-escalation to 8 mg allowed annually
Trial: 22129365
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg once daily; open-label treatment for ≥24 months
Trial: 10541949
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid regimen (60 ml/kg on day 1, increasing to 150 ml/kg by day 7)
Trial: 30478067
Drug: Ticagrelor therapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor therapy for 28 days
Trial: 29064792
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg once a day
Trial: 25296247
Drug: Study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug failure
Trial: 21959802
Drug: PVP K90
RxNorm normalized name: PVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP K90 160 mg/tablet
Trial: 16541114
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg oral daily tamsulosin (group 1, n=59)
Trial: 14506138
Drug: Two-weekly schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-weekly schedule of gemcitabine (1500 mg/m²) and cisplatin (90 mg/m²)
Trial: 14506138
Drug: Weekly schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly schedule of gemcitabine and cisplatin
Trial: 14506138
Drug: Two-weekly schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-weekly schedule
Trial: 14506138
Drug: Weekly schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly schedule
Trial: 8850048
Drug: Topical formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulations containing clobetasol propionate, doxepin hydrochloride, metronidazole, mupirocin, oxiconazole nitrate, and terbinafine hydrochloride
Trial: 8850048
Drug: Doxepin hydrochloride
RxNorm normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin hydrochloride cream vehicle
Trial: 1626168
Drug: Dolotren (D)
RxNorm normalized name: Dolorex Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolotren (D) 100 mg, administered b.i.d. for 15 days
Trial: 1626168
Drug: Dolotren Retard
RxNorm normalized name: Dolorex Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolotren Retard (DR) 100 mg, administered once a day for 15 days
Trial: 7416612
Drug: Subcutaneously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered epinephrine
Trial: 7416612
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered aminophylline
Trial: 31962198
Drug: Whole breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole breast irradiation (WBI) after endocrine therapy (ET)
Trial: 31962198
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (ET) alone (observation)
Trial: 20602715
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg once daily (QD) and increased to 120 mg QD at week 7 if < 30% pain reduction
Trial: 16829208
Drug: Angiogenesis inhibitor
RxNorm normalized name: Angiogenesis inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiogenesis inhibitor
Trial: 11707042
Drug: Single stage
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single stage head‐up tilt table test (HUT) with infusion of 3.44 microg/kg per hour of nitroglycerin
Trial: 11707042
Drug: Conventional multistage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional multistage test with infusion of nitroglycerin from 1.72 microg/kg per hour to 5.16 microg/kg per hour
Trial: 9597560
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day testosterone transdermal patch (T)
Trial: 9597560
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day testosterone transdermal patches (R)
Trial: 18713887
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of ketoprofen 1 mg/kg and fentanyl 1 microg/kg
Trial: 18713887
Drug: Baseline measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline measurements before premedication with midazolam 0.1 mg/kg IV
Trial: 10890862
Drug: Topical lodoxamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lodoxamide ophthalmic solution 0.1% (LOS)
Trial: 10890862
Drug: Topical cromolyn
RxNorm normalized name: cromolyn Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cromolyn sodium ophthalmic solution 4% (CSO)
Trial: 2996906
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pentoxifylline
Trial: 2996906
Drug: 12 micrograms/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 micrograms/ml pentoxifylline
Trial: 28611006
Drug: Atorvastatin 80mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80mg daily for one year
Trial: 28611006
Drug: Atorvastatin 10mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg daily for one year
Trial: 22000794
Drug: Pharyngeal anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharyngeal anesthesia with 4 squirts of lidocaine spray
Trial: 16563920
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) fenoldopam
Trial: 16563920
Drug: Intrarenal (IR)
RxNorm normalized name: mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarenal (IR) fenoldopam (2 hours after drug discontinuation)
Trial: 12062615
Drug: Two fractions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two fractions of high-dose-rate brachytherapy (9 Gy per application, 1 week apart)
Trial: 12062615
Drug: Concomitant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy (cisplatin 20 mg/m(2)/day for 5 days during EBRT)
Trial: 12062615
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose to rectum from high-dose-rate brachytherapy
Trial: 12062615
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose to bladder from high-dose-rate brachytherapy
Trial: 2253662
Drug: Ibopamine 400
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 400 mg t.d.s. for 5 to 10 days
Trial: 483202
Drug: Bromocriptine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 15 mg/day
Trial: 483202
Drug: Full medical
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full medical treatment
Trial: 30043207
Drug: PEG-rhG-CSF 100
RxNorm normalized name: PEG-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF 100 µg/kg, single subcutaneous injection 72 hours after chemotherapy
Trial: 30043207
Drug: rhG-CSF 5
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhG-CSF 5 µg/kg/day, subcutaneous injection once a day for 14 days or until ANC ≥ 10.0 × 10^9/l twice, starting 72 hours after chemotherapy
Trial: 17409825
Drug: Paclitaxel (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (15 mg/m/day)
Trial: 17409825
Drug: Paclitaxel (6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (6.5 mg/m/day)
Trial: 17409825
Drug: Paclitaxel (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (17 mg/m/day)
Trial: 17409825
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of paclitaxel with concurrent radiation therapy (RT)
Trial: 14635510
Drug: Bupropion 300
RxNorm normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 300 mg/day and nicotine patches
Trial: 10516865
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil in the late in-hospital phase of AMI without heart failure
Trial: 10516865
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil in the late in-hospital phase of AMI with heart failure
Trial: 10516865
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil combined with thrombolysis
Trial: 10516865
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil in the early phase of AMI
Trial: 1655136
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Fraxiparine) 41 IU/kg/day for three days, then 62 IU/kg/day from day 4 to day 10
Trial: 1655136
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin at intervals of eight hours, doses adjusted to maintain activated thromboplastin time at two to five seconds above control values
Trial: 6128021
Drug: Timolol (0.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (0.5-20 mg)
Trial: 6128021
Drug: Timolol (27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (27 ng/ml plasma concentration)
Trial: 30852479
Drug: Conventional anticancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anticancer drugs
Trial: 26587993
Drug: Acetazolamide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (up to 4 g/d)
Trial: 24583571
Drug: 10 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg of hypertonic saline (HTS) over 1 hour
Trial: 24583571
Drug: 10 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg of hypertonic saline (HTS)
Trial: 15903129
Drug: Paroxetine pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine pretreatment (20 mg daily for 3 consecutive days)
Trial: 15903129
Drug: Paroxetine/tramadol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine/tramadol combination
Trial: 15903129
Drug: Paroxetine in
RxNorm normalized name: Product containing paroxetine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine in combination with placebo
Trial: 10485389
Drug: Patch test
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch test for wheat
Trial: 8799415
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (mitomycin C and doxorubicin)
Trial: 8799415
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific anti-cancer treatment
Trial: 1633433
Drug: Phosphatidylserine (Fidia,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylserine (Fidia, 300 mg/d)
Trial: 6337787
Drug: Oral verapamil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil, 240 mg
Trial: 6337787
Drug: Digoxin, 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin, 0.25 mg and 0.5 mg daily
Trial: 6337787
Drug: Digoxin, 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin, 0.25 mg and verapamil
Trial: 30278529
Drug: Yufeining (YFN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yufeining (YFN) treatment
Trial: 22205316
Drug: Oral assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral assessment of size and shape
Trial: 20478383
Drug: Quercetin 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 1000 mg/day for 12 weeks
Trial: 18034195
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (short exposure, high-energy laser settings): exposure 0.02 s, 300 microm
Trial: 18034195
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (conventional settings): exposure time 0.1 s, power sufficient to produce visible grey-white burns, spot size 300 microm
Trial: 12356202
Drug: Nottingham Extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nottingham Extended Activities of Daily Living Scale (EADL)
Trial: 3162737
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment focusing on critical features of tooth anatomy and preparation methods
Trial: 3162737
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment with conventional written and oral descriptions
Trial: 27167219
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks ribavirin mono-therapy prior to adding pegIFN-α
Trial: 27167219
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks ribavirin double dosing concomitant with pegIFN-α
Trial: 27167219
Drug: standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α
Trial: 22660371
Drug: Constraint-induced movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced movement therapy (arm restriction)
Trial: 20156473
Drug: Perceptual learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceptual learning training (repeated measurements of visual-span profiles at 10 degrees below fixation, in four daily sessions)
Trial: 12427412
Drug: Isolated lower-limb
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated lower-limb training (3 months of low-level bicycle and treadmill exercise, minute ventilation <25 l/min)
Trial: 8649684
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg vasopressin diluted with 20 mL saline
Trial: 6360739
Drug: Tromantadine hydrochloride
RxNorm normalized name: Tromantadine hydrochloride
DrugBank: Tromantadine (DB13288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tromantadine hydrochloride (TH) ointment
Trial: 27931259
Drug: Extracorporeal veno-venous
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal veno-venous hemoperfusion therapy with the LPS Adsorber
Trial: 27931259
Drug: Veno-venous hemoperfusion
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veno-venous hemoperfusion therapy with a placebo adsorber (without active LPS-binding peptide)
Trial: 25155070
Drug: Time- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time- and dose-consistent PMI focused on general health (comparison condition)
Trial: 21896539
Drug: Capecitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1250 mg/m² twice daily for 24 weeks)
Trial: 17885017
Drug: Iron +
RxNorm normalized name: Celebrate Iron + C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron + folate supplements during pregnancy
Trial: 12116053
Drug: Epinephrine 2.5
RxNorm normalized name: epinephrine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 2.5 mg sublingual tablet
Trial: 12116053
Drug: Epinephrine 10
RxNorm normalized name: epinephrine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 10 mg sublingual tablet
Trial: 12116053
Drug: Epinephrine 0.03
RxNorm normalized name: epinephrine 0.032 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.03 mg IM injection (positive control)
Trial: 12116053
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl IM injection (negative control)
Trial: 9715843
Drug: ddI (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddI (200 mg every 12 hours) alone for 4 days
Trial: 9715843
Drug: ritonavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ritonavir (600 mg every 12 hours) alone for 4 days
Trial: 9715843
Drug: ddI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddI with ritonavir under dose-staggering conditions for 4 days
Trial: 8785890
Drug: PUVA combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA combined with topical corticosteroids
Trial: 8785890
Drug: PUVA combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA combined with calcipotriene ointment
Trial: 7364841
Drug: Negative pi
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Negative pi meson (pion) radiotherapy at a dose of at least 2700 peak pion rads, delivered at a rate of 100 to 125 rads daily.
Trial: 7364841
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation treatment (control group).
Trial: 26556603
Drug: SRT2104 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 (three escalating doses)
Trial: 25193004
Drug: DBT-PTSD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBT-PTSD treatment
Trial: 25193004
Drug: Treatment-as-usual wait-list
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual wait-list
Trial: 17257370
Drug: Thyroxine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine treatment (early start)
Trial: 15122959
Drug: Voucher‐based reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voucher‐based reinforcement therapy (VBRT) with donations for rewards in Toronto
Trial: 15122959
Drug: Voucher‐based reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voucher‐based reinforcement therapy (VBRT) with donations for rewards in Los Angeles
Trial: 12324553
Drug: Peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa‐2a plus ribavirin (180 microg once weekly + daily ribavirin 1000 or 1200 mg)
Trial: 12324553
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b plus ribavirin (3 million units thrice weekly + daily ribavirin)
Trial: 12324553
Drug: Peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa‐2a alone (weekly peginterferon alfa‐2a + daily placebo)
Trial: 9665239
Drug: DHE-PDT (4.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHE-PDT (4.25 mg/kg)
Trial: 9665239
Drug: DHE-PDT (3.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHE-PDT (3.25 mg/kg)
Trial: 8607303
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream applied 10 to 120 minutes before heel-lancing
Trial: 2590615
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg 'biphasic' nifedipine taken 12 hourly for 10 days
Trial: 28902084
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy (4 courses for LR, 6 courses for IR and HR) followed by restricted radiotherapy (RT) if partial remission. Low-dose involved field radiotherapy: 21 Gy plus 14 Gy boost for residual disease.
Trial: 28902084
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy (6 courses) followed by 21 Gy involved field radiotherapy for HR patients achieving CR.
Trial: 23873545
Drug: Infected group
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infected group (challenged with 10(5) ELD50/0.1 mL of infectious bronchitis virus)